Axogen rises after FDA approves co's nerve repair graft

Shares of Axogen AXGN.O gain 9.3% at $30.99 premarket after FDA approves its nerve repair graft

Avance Nerve Graft, a human tissue-based product, is designed to repair damaged peripheral nerves without requiring second surgery to harvest nerve tissue from the patient

Approval of the nerve graft paves the way for up to 12 years of potential U.S. market exclusivity, analysts say

Commercial sales of the licensed Avance product expected to begin early Q2 2026; until then, product continues under existing tissue framework

FDA approval reclassifies Avance as a biologic for treatment of sensory nerve discontinuities in adults and pediatric patients aged one month and older

AXGN stock up 71.9% YTD, as of last close